Provided by Tiger Fintech (Singapore) Pte. Ltd.

Exagen

3.56
+0.21006.27%
Post-market: 3.690.1299+3.65%18:54 EDT
Volume:48.90K
Turnover:173.55K
Market Cap:62.79M
PE:-4.29
High:3.66
Open:3.44
Low:3.44
Close:3.35
Loading ...

Exagen’s Positive Outlook: Buy Rating Backed by Strong Performance and Growth Potential

TIPRANKS
·
12 Mar

Exagen Inc (XGN) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives

GuruFocus.com
·
12 Mar

Q4 2024 Exagen Inc Earnings Call

Thomson Reuters StreetEvents
·
12 Mar

Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
11 Mar

Exagen Q4 2024 GAAP EPS $(0.20) Beats $(0.26) Estimate, Sales $13.65M Miss $13.85M Estimate

Benzinga
·
11 Mar

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

GlobeNewswire
·
11 Mar

Exagen Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
07 Mar

Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025

GlobeNewswire
·
26 Feb

Exagen Inc. (NASDAQ:XGN) Surges 40% Yet Its Low P/S Is No Reason For Excitement

Simply Wall St.
·
05 Feb

Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?

Zacks
·
05 Feb

US Penny Stocks To Watch In January 2025

Simply Wall St.
·
21 Jan

Exagen Gains 28%, Insider Trades Reap Benefit

Simply Wall St.
·
20 Jan

The 26% return this week takes Exagen's (NASDAQ:XGN) shareholders one-year gains to 102%

Simply Wall St.
·
19 Jan

Exagen Price Target Maintained With a $8.00/Share by Cantor Fitzgerald

Dow Jones
·
13 Jan

Analysts’ Top Healthcare Picks: Exagen (XGN), 10x Genomics (TXG)

TIPRANKS
·
13 Jan

Press Release: Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

Dow Jones
·
13 Jan